Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients With Cholangiocarcinoma
Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
Patients with advanced or metastatic cholangiocarcinoma (CCA) who are not eligible for
curative surgery, transplantation, or ablative therapies will receive nab-paclitaxel and
gemcitabine chemotherapy.
The purpose of this study is to evaluate the effectiveness and safety of the combination of
nab-paclitaxel and gemcitabine. The effectiveness will be determined by improvement in the
length of time during and after treatment, that the CCA does not get worse.